CatalYm

About

CatalYm is a biotechnology company developing innovative immunotherapies for cancer patients.

Planegg,Bayern,Germany
1 - 10
http://www.catalym.com

Highlights

Details

Last Funding Type: Series C
Last Funding Money Raised: €50M
Industries: Biotechnology,Health Care,Medical,Therapeutics
Founded date: Jan 1, 2016
Number Of Employee: 1 - 10
Operating Status: Active
Legal Name: CatalYm GmbH

CatalYm is a biotechnology company committed to developing innovative immunotherapies for cancer patients. CatalYm has identified GDF-15 as a central regulator of the immune system in the tumor microenvironment and translates the therapeutic potential of neutralizing GDF-15 into meaningful clinical responses for patients with solid tumors. CatalYm’s CTL-002 program is poised to demonstrate clinical proof-of-concept in multiple solid tumor indications and has the potential to expand the treatment horizon for current and future immunotherapies.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

3

€100M

CatalYm has raised a total of €100M in funding over 2 rounds. Their latest funding was raised on Nov 22, 2022 from a Series C round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Nov 22, 2022	Series C	€50M	8	Brandon Capital Partners Jeito Capital	—	Detail
Nov 19, 2020	Series B	€50M	6	Vesalius Biocapital Partners	—	Detail
Aug 5, 2016	Seed	—	1	—	—	Detail

Investors

Number of Lead Investors

Number of Investors

3

9

CatalYm is funded by 9 investors. Brandon Capital Partners and Jeito Capital are the most recent investors.

Investor Name	Lead Investor	Funding Round
Brandon Capital Partners	Yes	Series C
Jeito Capital	Yes	Series C
Bayern Kapital	—	Series C
BioGeneration Ventures	—	Series C
coparion	—	Series C
Forbion Capital Partners	—	Series C
Novartis Venture Fund	—	Series C
Vesalius Biocapital Partners	—	Series C
Wachstumsfonds Bayern	—	Series B